BackBristol-Myers Squibb Overview

Bristol-Myers Squibb Long Term Debt

Track Bristol-Myers Squibb's long-term debt ($44B) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$43.56B
↓ 2.04% YoYΔ $-907.00M vs prior year quarter

Peer trimmed avg / median

Loading

Bristol-Myers Squibb Long Term Debt History

Loading

Bristol-Myers Squibb vs. peers: Long Term Debt Comparison

Loading

Bristol-Myers Squibb Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Bristol-Myers Squibb (BMY) FAQ

The latest long-term debt for BMY is $44B as of September 2026. That compares with $44B in the prior-year period — down 2.0% year over year. Investors often review this figure alongside Bristol-Myers Squibb's historical trend and sector peers before judging valuation or financial health.

Over the past year, BMY's long-term debt moved from $44B to $44B — a 2.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Bristol-Myers Squibb's operating scale or balance-sheet position.

A long-term debt figure of $44B for BMY is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting BMY's long-term debt ($44B), review year-over-year change from $44B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Bristol-Myers Squibb's long-term debt against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.